Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | JUN | P05412 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881470 | 1.00 | CYP11B1 (0.61) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL457159 | 1.00 | CYP11B1 (0.61) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL6249186 | 0.92 | CYP11B1 (0.57) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL27626846 | 0.92 | CYP11B1 (0.57) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL29691639 | 0.82 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL29691623 | 0.82 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL6655801 | 0.81 | MKNK1 (0.49) | CYP11B1CYP11B2MAPK1MEN1LMNA | |
| SCHEMBL6655803 | 0.81 | MKNK1 (0.49) | CYP11B1CYP11B2MAPK1MEN1LMNA | |
| SCHEMBL29691514 | 0.80 | CYP11B1 (0.82) | CYP11B1CYP11B2RAB9AMAPTNPC1 | |
| SCHEMBL29691548 | 0.80 | CYP11B1 (0.82) | CYP11B1CYP11B2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095698-A1 | ELECTROLYTIC TIN PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-03-26 | — | — | US | claimed |
| JP-7233149-A | — | — | None | — | — | JP | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| EP-4164654-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20010031768-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| EP-0841327-B1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-5977152-A | Triazole antifungal agent | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| CN-1187191-A | Triazole antifungal agents | SANKYO CO (JP) | 1998-07-08 | — | — | CN | disclosed |
| EP-0841327-A1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
| JP-H07233149-A | CHLOROBENZENESULFONYLAMIDO(3-PYRIDYL) ALKYLPHENYLPROPIONIC ACID DERIVATIVE | TERUMO CORP | 1995-09-05 | — | — | JP | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| WO-1992005148-A1 | IMIDAZOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATIONS | RHONE-POULENC RORER LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031768-A1 | Triazole antifungal agent | ERG28, RIF1, NAT1 | CYP11B1 232/4885CYP11B2 251/4885RAB9A 1269/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | CYP11B1 3368/4885CYP11B2 3593/4885RAB9A 1211/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | CYP11B1 3368/4885CYP11B2 3593/4885RAB9A 1211/4885 |
| US-20230265094-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | CYP11B1 2305/4885CYP11B2 2740/4885RAB9A 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.